Schonfeld Strategic Advisors LLC Supernus Pharmaceuticals, Inc. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $112,214 - $146,589	-4,939 Reduced 13.29%	32,219 $932,000
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $1.7 Million - $2.03 Million	-61,730 Reduced 62.42%	37,158 $1.02 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $740,122 - $958,373	-24,745 Reduced 20.01%	98,888 $2.97 Million
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $2.02 Million - $2.43 Million	57,728 Added 87.59%	123,633 $4.48 Million
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $1.53 Million - $1.86 Million	49,105 Added 292.29%	65,905 $2.35 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $483,672 - $594,888	16,800 New	16,800 $569,000
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $2.02 Million - $2.73 Million	-79,801 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $1.92 Million - $2.22 Million	67,501 Added 548.79%	79,801 $2.58 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $324,351 - $420,906	12,300 New	12,300 $359,000
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $726,798 - $850,594	-19,967 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $733,787 - $991,361	19,967	19,967 $799,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.